EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Current Management Guidelines on Hyperlipidemia: The Silent Killer

Lilly Su iD, Rea Mittal iD, Devyani Ramgobin iD, Rahul Jain, Rohit Jain

Journal of Lipids · 31.07.2021 · 2021 · 1-5

DOI: 10.1155/2021/9883352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Lipids, erschienen am 31.07.2021. Verfasst von Lilly Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Pennsylvania State College of Medicine, Hershey, PA, USA. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the high incidence of cardiovascular events in the United States, strict control of modifiable risk factors is important. Pharmacotherapy is helpful in maintaining control of modifiable risk factors such as elevated lipids or hypercholesterolemia. Hypercholesterolemia can lead to atherosclerotic disease which may increase the risk of acute coronary events. Statin therapy has long been a mainstay in the treatment of hypercholesterolemia, but while highly regarded, statin therapy also has side effects that may lead to patient noncompliance. Therefore, various medicines are being developed to manage hypercholesterolemia. This paper will discuss the role that lipids play in the pathophysiology of atherosclerotic disease, review the current lipid management guidelines, and discuss new treatment options that are alternatives to statin therapy.

Autor:innen und Institutionen

  • School of Medicine, Pennsylvania State College of Medicine, Hershey, PA, USA.
  • Touro College of Osteopathic Medicine, Middletown, NY, USA.
  • Indiana University School of Medicine, Indianapolis, IN, USA.
  • Department of Internal Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.

ORCID-Profile: Lilly Su, Rea Mittal, Devyani Ramgobin

Zitieren

APA

Su, L., Mittal, R., Ramgobin, D., Jain, R., & Jain, R. (2021). Current Management Guidelines on Hyperlipidemia: The Silent Killer. Journal of Lipids, 2021, 1-5. https://doi.org/10.1155/2021/9883352

Vancouver

Su L, Mittal R, Ramgobin D, Jain R, Jain R. Current Management Guidelines on Hyperlipidemia: The Silent Killer. Journal of Lipids. 2021;2021:1-5. doi:10.1155/2021/9883352

BibTeX
@article{Su2021,
  author = {Su, Lilly and Mittal, Rea and Ramgobin, Devyani and Jain, Rahul and Jain, Rohit},
  title = {Current Management Guidelines on Hyperlipidemia: The Silent Killer},
  journal = {Journal of Lipids},
  year = {2021},
  volume = {2021},
  pages = {1--5},
  doi = {10.1155/2021/9883352}
}
Kostenlos starten →